Daily Management Review

Sanofi buys Belgium's Ablynx for € 3.9 billion


01/29/2018


The deal is another sign of M&A activity in the global biotech sector. Earlier, Ablynx rejected a purchase offer for € 2.6 billion from the Danish Novo Nordisk.



Sanofi will pay € 45 per share in cash to Ablynx with a 21.2% premium on the closing price on Friday.

The French company said that Ablynx would increase the long-term value for its shareholders. At the same time, the takeover is expected to have a neutral impact on Sanofi's earnings per share in 2018 and 2019.

Sanofi is already one of the major pharmaceutical partners of Ablynx after the deal in July 2017, devised to find new methods for the treatment of inflammatory diseases.

Having bought the Belgian company, Sanofi will have access to the most promising asset of Ablynx, the experimental drug Caplacizumab for the treatment of a rare bleeding disorder.

At the beginning of January 2018, the Danish pharmaceutical company Novo Nordisk made a proposal to acquire Ablynx, assessing the Belgian company at 2.6 billion euros (3.2 billion dollars) or 28 euros per share. The management of Ablynx felt that the company was undervalued.

The Sanofi offer represents a 48% premium to the offer of Novo Nordisk.

According to informed sources, after the rejection of Novo Nordisk's proposal, the Belgian company was expecting offers from Sanofi, Merck & Co. (outside the US and Canada - MSD) and Roche.

Ablynx’s most promising drug under development is Caplacizumab, intended for the treatment of acquired thrombotic thrombocytopenic purpura. In February 2017, the Belgian company sent an application for approval to the EMA. The filing of an application with the FDA is scheduled for the first half of 2018.

In addition, Ablynx is developing a drug for the treatment of respiratory syncytial virus ALX-017. Currently, the IIb stage of clinical trials is under way.

This month, there was a surge in multibillion-dollar deals in the field of biotechnology. For example, the American biotechnology company Celgene, specializing in drugs for the treatment of cancer and inflammatory diseases, announced the acquisition of its competitor Juno Therapeutics for $ 9 billion.

These transactions are caused by the need for large pharmaceutical companies to gain access to new promising medicines, developed by their smaller competitors.

Last week, Sanofi agreed to buy an American Bioverativ, which specializes in preparations for the treatment of hemophilia and other rare blood diseases, for $ 11.6 billion. This is Sanofi's largest transaction in seven years.

source: reuters.com






Science & Technology

Germany Introduces The First Ever Train To Run On 100% Hydrogen

Germany Plans On Cyber Security Research To End Reliance On U.S. Tech

Fuchsia will kill Android by 2023: Top 5 facts about the new OS

New Study Finds Goats Interact More With Happy People

More than 32 thousand "smart" houses under threat of hacker attack

Internet addiction and children: Global plague

Apple takes up to develop Apple Watch for health monitoring

Hyperloop is growing in Europe

Analysts: US gamers prefer mobile games

Google Assistant Winner Of Head-To-Head Test Of Digital Assistants, Beats Siri And Alexa

World Politics

World & Politics

Ex-Brexit Minister Said A ‘Reset’ Is Needed For Brexit Talks

10 countries with the best healthcare systems

Foreign Experts To Be Allowed By North Korea For Permanent Destruction Of Missile Sites

Ireland recovers €14.3 billion from Apple

Is China going to cancel its birth limit policy?

The US is ready to start negotiations with China

US and China start 5G race

Is Czech Republic posing a threat to the European Union?